The healthcare and pharmaceutical reports of EMIS Insights covers the healthcare services and institutions, the relevant government policy and insurances, as well as the manufacturing and sales of medicines. We report on number of public and private hospitals, hospital beds, number of medical staff, number of patients and length of stay in hospitals and outpatient clinics. The mandatory and voluntary health insurances, as well as the lists of reimbursable medicines are being covered. The pharmaceutical sector coverage is split into manufacturing and distribution of branded and generic, as well as prescription and OTC drugs.
Each report contains in-depth analysis of the sector’s importance for the country’s economy, detailed statistics and infographics. The report includes executive summary, sector and subsector overviews, competitive and regulatory environment, as well as thorough company profiles of the top market players.
China is the world’s second largest pharmaceutical market after the US and the largest producer and exporter of active pharmaceutical ingredients (APIs) globally. Since it is the world’s most populous country, with a large share of ageing ...READ MORE
China is the world’s second largest pharmaceutical market after the US and the largest producer and exporter of active pharmaceutical ingredients (APIs) globally. Since it is the world’s most populous country, with a large ageing ...READ MORE
India’s 1.3-bn population has given rise to a sizeable healthcare sector and one of the largest pharmaceutical markets in Asia. Both the healthcare and drug markets are plagued by uneven geographical spread, low levels of public expenditure and ...READ MORE
China's healthcare system is hospital-centric, with public hospitals delivering approximately 90% of the inpatient and outpatient care consumed in the country in both hospitals and basic medical institutions. Nearly 40% of hospitals’ revenue is ...READ MORE
The Philippines healthcare and pharmaceuticals sector has grown gradually in past years due to the country’s population and economic growth. Recently, sector growth has accelerated due to policy measures to increase the healthcare budget which ...READ MORE
Indonesia's healthcare and pharmaceuticals industry is one of the least developed in ASEAN and Indonesia has low scores on most metrics – including number of hospitals and beds per 10,000 population and healthcare expenditure per capita. These ...READ MORE
The Malaysian healthcare and pharmaceuticals sector has been growing strongly as a result of factors including one of the highest population growth rates in the ASEAN region, increasing affluence, and growing access to healthcare funding. In ...READ MORE
Thailand is the second-largest pharmaceutical market in South East Asia, with sales of THB 152.9bn in 2015. The pharmaceutical industry specialises in generic drug production and this is the largest segment on the market. Spending on health is ...READ MORE
In 2015, the total Hungarian healthcare expenditure amounted to HUF 2,373.4bn, or 7.04% of GDP. Public financing schemes made up 67.1% of the healthcare spending. By regional standards, the Hungarian health spending as a percentage of GDP is high, ...READ MORE
China is the world’s second-largest pharmaceutical market, after the US, and the largest producer and exporter of active pharmaceutical ingredients (APIs) globally. Since it is the world’s most populous country, with a large ageing ...READ MORE